SEATTLE, Wash. and VANCOUVER, British Columbia, September 4, 2019 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences. H.C. Wainwright 21st Annual Global…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, August 8, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced second quarter 2019 financial results. Q2 2019 Highlights Reported positive results…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, July 30, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019. Company management will host a conference…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, July 23, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH). Under the extended collaboration, the NIH…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14,…
/Read More